Organisation paid for research Program year 2025 Source: CMS Open Payments

Shreenath Clinical Service

Neither a doctor nor a teaching hospital

Research payments

$3,896,085

509 payments

Through program year 2025, Shreenath Clinical Service is reported as receiving $3,896,085 in research payments, across 509 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $183,661 5
2024 Research $189,290 3
2023 Research $389,842 11
2022 Research $321,521 14
2021 Research $399,951 10
2020 Research $1,143,115 33
2019 Research $1,268,705 433

Breakdown

Who paid Research payments · program years 2019–2025
  1. Otsuka Pharmaceutical Development & Commercialization, Inc. $3,085,933 22 payments
  2. Akebia Therapeutics Inc $604,895 458 payments
  3. E.R. Squibb & Sons, L.L.C. $115,459 3 payments
  4. Celgene Corporation $48,480 1 payment
  5. AstraZeneca Pharmaceuticals LP $17,442 2 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $10,800 1 payment
  7. Novo Nordisk AS $6,350 5 payments
  8. Eisai Inc. $5,700 2 payments
  9. AstraZeneca AB $750 1 payment
  10. Daiichi Sankyo Inc. $276 14 payments
Studies the money was for Research payments · program years 2019–2025
  1. Protocol 331-201-00081 A Multicenter, Randomized, Double-Blind Trial of Brexpiprazole Versus Placebo for the Acute Treatment of Manic Episodes, With Or Without Mixed Features, Associated With Bipolar I Disorder $499,454 1 payment
  2. A Phase 3, 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 2-Arm, Fixed-Dose Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole (Opc34712) in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimers Type $475,581 1 payment
  3. A Phase 3, Multicenter, Randomized, Double-Blind Trial of Fixed-Dose Brexpiprazole As Combination Therapy With Sertraline in the Treatment of Adults With Post-Traumatic Stress Disorder $429,747 3 payments
  4. A 12-Week, Multicenter, Active-Treatment Extension Trial to Evaulate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type $369,721 2 payments
  5. A Phase 3, 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 2-Arm, Fixed-Dose Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole Opc34712 in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimers Type $361,641 1 payment
  6. A 12-Week, Multicenter, Active-Treatment Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type $272,328 3 payments
  7. A Phase 3, 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 2-Arm, Fixed-Dose Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole (Opc-34712) in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimers Type $251,877 3 payments
  8. Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Correction of Anemia in Subjects With Non-Dialysis-Dependent Chronic Kidney Disease (Ndd-Ckd) (Pro2tect-Correction) $194,318 13 payments
  9. Akb-6548-Ci-0014 $189,374 318 payments
  10. A Phase 2, Randomized, Double-blind, Three-Arm, Placebo-controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of orally administered BMS-986368, a FAAH/MAGL Inhibitor, for the treatment of Agitation in Participants with Alzheimer's Disease $147,325 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record